Also known as: Rett's syndrome, RTT
Almost exclusively affects girls and women; affected males are rare and typically more severely affected. Mutations in MECP2 gene on X chromosome. De novo mutations in 99% of cases, so family history is rare. Symptoms typically appear ages 6-18 months after normal development.
Gene therapy approaches for Rett syndrome are in clinical trials, including MECP2 gene replacement therapy delivered to the brain. These early-stage studies show promise for halting or reversing neurological decline. The International Rett Syndrome Foundation (IRSF) and patient registries provide information on clinical trials. Discuss with your neurologist about potential trial eligibility, particularly gene therapy studies. Additional trials are evaluating trofinetide, which enhances neuroplasticity and has shown benefit in slowing decline. Early supportive care including seizure management, respiratory support, and physical/occupational therapy optimizes outcomes and quality of life.
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...